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Essentials
• Inhibitors of protein disulfide isomerase (PDI) have been considered a new antithrombotic class.
• CxxC is a PDI-targeted peptide that has been previously shown to inhibit its reductase activity.
• CxxC binds to surface PDI and inhibits ADP-and thrombin-evoked platelet activation and aggregation.
• CxxC binds to Cys 400 on CGHC redox motif of PDI a' domain, a site for PDI prothrombotic activity.
Summary. Background: Protein disulfide isomerase (PDI) plays a major role in platelet aggregation, and its inhibitors have emerged as novel antithrombotic drugs. In previous work, we designed a peptide based on a PDI redox motif (CGHC) that inhibited both PDI reductase activity and PDI-modulated superoxide generation by neutrophil Nox2. Thus, we hypothesized that this peptide would also inhibit platelet aggregation by association with surface PDI. Methods: Three peptides were used: CxxC, containing the PDI redox motif; Scr, presenting a scrambled sequence of the same residues and AxxA, with cysteines replaced by alanine. These peptides were tested under platelet aggregation and flow cytometry protocols to identify their possible antiplatelet activity. We labeled membrane free thiol and electrospray ionization liquid chromatography tandem mass spectrometry to test for an interaction. Results: CxxC decreased platelet aggregation in a dose-dependent manner, being more potent at lower agonist concentrations, whereas neither AxxA nor Scr peptides exerted any effect. CxxC decreased aIIbb3 activation, but had no effect on the other markers. CxxC also decreased cell surface PDI pulldown without interfering with the total thiol protein content. Finally, we detected the addition of one CxxC molecule to reduced PDI through binding to Cys400 through mass spectrometry. Interestingly, CxxC did not react with oxidized PDI. Discussion:
Introduction
Protein disulfide isomerase (PDI) is the prototypic member of an oxidoreductase family of enzymes, the PDI family, whose primary function is to catalyze redox protein folding in the endoplasmic reticulum (ER) [1] . Based on a multidomain structure, the role of PDI in disulfide oxidation, reduction and isomerization reactions requires vicinal thiols in its catalytic motifs (CGHC), located in the a and a 0 domains [2] , besides a substrate-binding hydrophobic pocket located in the b 0 domain [3] . Outside of the ER, PDI has also been found on the cell surfaces of several cell types, such as lymphocytes, neutrophils, and particularly platelets, where this enzyme is functionally active and has proved to be critical to thrombus formation [4] [5] [6] .
PDI inhibitors, such as bacitracin, scrambled RNase, or anti-PDI antibodies, inhibit platelet activation and aggregation [5] . In addition, they inhibit the activation of a IIb b 3 [7] , a polythiol integrin found exclusively on platelet surfaces, and that promotes platelet binding to soluble fibrinogen and von Willebrand factor [8] . Mn 2+ -induced a IIb b 3 activation does not depend on intracellular signaling, and is also inhibited by anti-PDI antibodies, suggesting a close interaction between a IIb b 3 and platelet surface PDI [9] . Other membrane thiol proteins, such as glycoprotein Iba [10] and collagen receptor a 2 b 1 [11] , are also regulated by PDI. PDI inhibits ADP-induced platelet aggregation, although it does not interfere with the P2Y 12 ADP receptor, whose free thiols are targeted by clopidogrel [9, 12] . Therefore, PDI is a converging hub for different signaling pathways of platelet aggregation, mainly by means of a IIb b 3 modulation via thiol-disulfide exchange [5, 9, 13] .
Although it is ubiquitous, PDI has emerged as a novel antithrombotic target, particularly because it involves mechanisms different from those targeted by current therapies, namely coagulation cascade proteins, platelet receptors, and classic platelet signaling proteins [14, 15] . Recently, several low molecular weight molecules, both natural and synthetic, have been reported to promote antiplatelet effects through selective PDI inhibition, e.g. quercetin-related flavonoids containing an O-glycosidic linkage in ring 3 [15] , mastoparan, a wasp venom tetradecapeptide that inhibits platelet-derived tissue growth factor-b1 activation [16] , and bepristat analogs 1a and 2a, which bind to the hydrophobic pocket at the b 0 domain of PDI [17] .
We recently showed that a dodecapeptide mimicking the CGHC active site of PDI (CxxC) inhibited both PDI reductase activity and PDI-modulated superoxide generation by neutrophil Nox2 [18] . Thus, we hypothesized that CxxC would inhibit platelet aggregation by association with surface PDI. In the present report, we demonstrate that CxxC inhibits both ADP-induced and thrombininduced platelet aggregation, decreases a IIb b 3 activation, and reduces PDI-associated thiol availability on platelet surfaces. Such effects are ascribed to covalent binding of CxxC to Cys400 in the PDI a 0 domain. These data support the vital role of the C-terminal CGHC redox motif for PDI's activity in platelet aggregation, and suggest that CxxC can be further exploited as a model for site-driven antithrombotic agent development.
Materials and methods

Peptide design and synthesis
The peptides were designed on the basis of the linear sequence of PDI's active sites (accession number P21195). For design purposes, we took into consideration the redox motifs of PDI (CGHC) in both the a domain and the a 0 domain (Fig. 1) . Thus, we designed the following peptides (USPTO pending patent PCT/BR2016/050170, 22 July 2016) carrying an acetyl group at the C-terminal residue, and an amide at the N-terminal residue acid (Fig. 1, bottom panel) : (i) CxxC (VEFYAPWCGHCK), analogous to the sequences containing the redox motifs from Val46-Lys57 and Val390-Lys401; (ii) AxxA (VEFYAPWAGHAK), with the same sequence as CxxC, except that Cys residues are replaced with Ala residues; (iii) Scr (FCYPKACEWGHV), containing the same residues of CxxC in random sequence without forming vicinal thiols. Peptide synthesis was performed by EZ Biolab (Carmel, IN, USA), and peptides showed a purity of > 95%. For all experimental assays, the redox state of the peptides in aqueous solution was assessed with the DTNB reagent [19] , and peptides were used in their reduced state.
Preparation of platelet-rich plasma (PRP) and washed platelets Blood samples were obtained from self-declared healthy volunteers who had not used antiplatelet medications for at least 10 days prior to venipuncture. Informed consent was obtained and the protocols were approved by Comitê de Etica em Pesquisa of the Federal University of Maranhão, identified as 017432/2011-29. Blood samples were collected by venipuncture into acid-citrate-dextrose (ACD) tubes, and centrifuged at 200 9 g for 10 min to obtain PRP. To obtain washed platelets (WPs), we used a previously described method [20] . Briefly, PRP was centrifuged at 800 9 g for 10 min at room temperature, and the remaining pellet was resuspended in Ca 2+ -free Tyrode's buffer (134 mM NaCl, 12 mM NaHCO 3 , 2.9 mM KCl, 0.34 mM Na 2 HPO 4 , 1 mM MgCl 2 , 10 mM HEPES, 5 mM glucose, pH 7.4) containing ACD (Tyrode's/ACD 9 : 1 v/v). Platelets were once again centrifuged at 800 9 g for 10 min and resuspended in Ca 2+ -free Tyrode's buffer, and WPs were used within 5 h. 
Electrospray ionization (ESI) liquid chromatography (LC)-tandem mass spectrometry (MS/MS) studies and peptide mapping
Human recombinant PDI was obtained with a method described in a previous report from our group [18] . Reduced PDI was prepared by incubating the enzyme with dithiothreitol in a 10 : 1 ratio for 30 min at room temperature. Oxidized PDI was prepared in accordance with Brophy et al. [16] by incubating the enzyme overnight with 10 mM glutathione disulfide (GSSG). Excess GSSG was removed with a PD-10 Sephadex G-25 column (Sigma-Aldrich Brasil Ltda., Sa˜o Paulo, Brazil) equilibrated with phosphate-buffered saline. Both reduced and oxidized PDI (1 lM) were incubated in the absence or presence of CxxC (6 lM) or Scr (6 lM) for 1 h at room temperature. In all cases, after the reaction mixture had been passed through centrifugal filter devices (Merck KGaA, Darmstadt, Germany), the protein was analyzed in a hybrid triple quadrupole/linear ion trap mass spectrometer (QTRAP 4500; ABSciex, Framingham, MA, USA). The protein was separated in a C4 column (5 lm, 150 9 1 mm; Grace Vydac, Hesperia, CA, USA), and eluted with solvent A (0.1% formic acid) and solvent B (0.1% formic acid in acetonitrile) at a flow rate of 0.1 mL min À1 by use of the following solvent gradient:
0-2 min, 5% solvent B; 2-10 min, 5-50% solvent B; 10-20 min, 50% solvent B; and 20-21 min, 5-50% solvent B. Re-equilibration to the initial condition was then performed for 15 min. The electrospray voltage was 5 kV, and the capillary temperature was 300°C [21] . The protein mass spectrometry analysis was performed in positive ion mode; data were acquired and analyzed with AN-ALYST 1.6.1 software (ABSciex). The results were processed with PEAK VIEW software (ABSciex) to obtain the protein molecular weight.
To determine the site of covalent adduction, trypsinization of the enzyme followed by LC-MS/MS analysis was performed. Reduced PDI treated or not treated with the peptides was digested overnight in 50 mM pyrophosphate buffer (pH 7.4) with sequencinggrade trypsin, at an enzyme/substrate ratio of 1 : 50 (w/w). Peptides were separated in a reversed-phase column (5 lm, 2.1 9 150 mm, 300
A; Grace Vydac), and eluted with solvent A (0.1% formic acid) and solvent B (0.08% formic acid in acetonitrile). Peptides were eluted at 40°C at a flow rate of 0.25 mL min À1 with a linear gradient of solvent B (2-60% in 105 min). The electrospray voltage was 5 kV, and the capillary temperature was 260°C. Peptide MS and MS/MS analyses with the QTRAP4500 were performed in positive ion mode with a mass range of 100-2000. Peptide analysis was performed and y and b series were obtained with PEAK VIEW software, and identification of the protein was performed by comparing the obtained peptides with data in MASCOT (Matrix Science, London, UK) [21] .
Statistical analysis
The quantitative results were expressed as mean AE standard error of the mean of three independent experiments per protocol. One-way ANOVA was performed, with a Newman-Keuls post hoc test, and a P-value of < 0.05 was considered to be significant.
Results
CxxC decreases ADP-evoked and thrombin-evoked platelet aggregation
We first assessed the roles of CxxC, AxxA and Scr in platelet function. As shown in Fig. 2A-D, 30 lM CxxC decreased ADP-triggered platelet maximal aggregation in PRP by 70% and 28%, respectively, when 2.5 lM or 5.0 lM of ADP was used. Probably, 30 lM CxxC also inhibited thrombin-induced platelet aggregation ( Fig. 2E-H) , suggesting CxxC effects to be independent of the selected agonist. The antiplatelet effect of CxxC was then analyzed in WPs (Fig. 3) . CxxC dose-dependently inhibited platelet aggregation (Figs 3A,B, S1 and S2), whereas no effect was observed for AxxA or Scr in any experiment (Figs 2, 3C,D and S2). Nevertheless, we coincubated CxxC with different anti-PDI antibodies, namely RL90 and BD34, to examine possible synergism between these compounds ( Fig. 3E-H) . None of the antibodies had their effects amplified by CxxC, whereas RL90
enhanced CxxC-induced platelet aggregation inhibition. Overall, these results suggest that CxxC strongly inhibits platelet aggregation without exerting additional effects on anti-PDI antibody inhibition.
CxxC diminishes a IIb b 3 activation on the platelet surface
The role of CxxC in platelet activation was investigated with flow cytometry, to measure the expression of (Fig. 4A-D, PAC-1), P-selectin (Fig. 4E-H , CD62-P) and granulophysin (Fig. 4I-L, CD63 ) on resting and thrombin-activated platelets. All three markers statistically increased surface expression upon activation (Fig. 4D,  H,L) . Incubation of 10 lM CxxC prior to platelet activation decreased a IIb b 3 activation and mean fluorescence intensity (MFI) by approximately 30% and 66%, respectively (Fig. 4D,E) , whereas no effect was observed on P-selectin and granulophysin (Fig. 4H,L) . Both AxxA and Scr showed no effects on surface expression of any marker. This set of data reinforces the idea that CxxC reduced a IIb b 3 activation without interfering with granule secretion.
CxxC diminishes PDI free thiol availability on the platelet surface
To analyze the possible association of CxxC and its control peptides with PDI free thiols on the platelet surface, resting platelets were incubated with the membrane-impermeable biotinylated reagent MPB. Figure 5A shows that exposure of resting platelets to 1 mM TCEP, a membrane-impermeable thiol reductant, resulted in a nearly 2.5-fold increase in MPB labeling. The presence of the peptides did not significantly alter MPB binding to total surface free thiols (Fig. 5B) . Assessment of MPB binding to surface PDI showed a four-fold increase in MPB labeling in the presence of TCEP (Fig. 5C ). On the other hand, when CxxC (25 lM) was present, MPB binding to surface PDI was significantly diminished by~30%, whereas AxxA and Scr had no effect (Fig. 5D) . It is noteworthy that thiol reduction by TCEP did not affect the intracellular PDI content, which was assessed in the post-MPB supernatant (Fig. 5C,D , lower right panels). These data allow us to hypothesize that CxxC covalently binds to surface PDI without affecting total free thiol pulldown from the resting platelet membrane.
CxxC covalently binds to the C-terminal active site of PDI
The probable association of CxxC with PDI was addressed through its in vitro reaction with recombinant human PDI followed by MS analysis. The spectral data in Fig. 6A-C show a peak of 60 497 Da, which corresponds to the reduced form of the recombinant protein.
In contrast, oxidized PDI ( Fig. 6D-F) showed two peaks, in accordance with the presence of one (61 110 Da) or two (61 720 Da) PDI-GSSG adducts. When CxxC was present, reduced PDI spectra showed the appearance of a peak of 61 978 Da (Fig. 6B ), in accordance with the addition of 1481 Da, equivalent to the mass of CxxC (Fig. S3) . No additional peak was found in the presence of Scr (Fig. 6C) , either when the oxidized PDI was incubated with CxxC (Fig. 6E) or when it was incubated with Scr ( Fig. 6F) . Upon trypsinization, peptide mass mapping of reduced PDI by ESI LC-MS/MS in the absence or presence of CxxC showed coverage of almost 80% of the PDI primary sequence (Fig. S4) . The fragment containing Lys386-Lys401, which includes both cysteines (Cys397 and Cys400) from the PDI a 0 domain, was the only one to show a different observed mass and a different retention time when it reacted with CxxC ( Fig. 6D,E) (Figs. 6C and S3 ). As shown in Fig. 6E , such a difference was found from a comparative analysis of the double-charged fragments y 2 , y 4 , y 6 and b 16 from PDI-CxxC reactions. On the other hand, no difference was found in fragment b 13 , the only one to contain Cys397 but not Cys400. Therefore, these results clearly demonstrate that CxxC covalently binds to Cys400 on the PDI a 0 domain, probably through a mixed disulfide bond.
Discussion
PDI has long been known to be of vital importance for platelet function and thrombus formation [4] [5] [6] , and has recently emerged as a prominent target for antithrombotic therapy [14, 15] . In a previous study, we demonstrated that CxxC, a dodecapeptide mimicking the PDI active redox site, inhibited PDI reductase activity [18] . Here, we expand CxxC's actions by demonstrating a novel antiplatelet role for this peptide, whose inhibitory effects on platelet activation and aggregation seem to be related to its covalent binding to Cys400 in PDI.
CxxC incubation promoted dose-dependent inhibition of human platelet aggregation, reaching its maximum effect at 30 lM in PRP (Fig. S1 ) and at 10 lM in WPs (Fig. S2) , with more prominent effects being seen at lower concentrations of agonists (Figs 2 and S2 ). This is consistent with a previous study showing that PDI-null platelets had 30-40% lower aggregation upon ADP or thrombin activation, an effect that was overcome at higher concentrations of agonists [22] . These authors also demonstrated that BD34, a monoclonal anti-PDI antibody, inhibited thrombin-triggered aggregation in wild-type but not in PDI-null platelets, suggesting that BD34 does not inhibit platelet thiol isomerases other than PDI [22] . In contrast, anti-PDI RL90 has been shown to also inhibit ERp57 activity [23] . Therefore, we coincubated CxxC with anti-PDI RL90 or BD34 to assess a possible associative effect (Fig. 3E-H) . Interestingly, CxxC did not enhance the level of inhibition of any antibody used, whereas coincubation with CxxC and RL90 did promote additional inhibition of platelet aggregation as compared with CxxC alone, meaning that RL90 targets molecules that CxxC does not. Thus, these results allow us to hypothesize that CxxC reduces platelet aggregation by inhibiting PDI, possibly without affecting other thiol isomerases, as no additive effect was observed under similar experimental conditions when BD34 was coincubated with the peptide.
We then used flow cytometry to determine whether CxxC affected platelet membrane glycoproteins that, upon activation, either change conformation (a IIb b 3 integrin) or become exposed (P-selectin and granulophysin). CxxC reduced the binding of PAC-1 to activated platelets by 30%, whereas MFI was reduced by 66% (Fig. 4D,E) , suggesting less intense activation. This is compatible with our data on platelet aggregation, and similar to the findings of another study showing decreased a IIb b 3 activation in PDI-null platelets [22] . It is of note that CxxC did not interfere with P-selectin or granulophysin membrane exposure (Fig. 4F-O) . Our data on P-selectin are in agreement with those from other studies [7, 17, 22] , despite a contrasting report describing decreased P-selectin exposure in PDI-null platelets [24] . However, the fact that CxxC did not inhibit granulophysin exposure was not expected, as some reports have shown that PDI inhibition decreases ATP secretion, suggesting that dense granule exocytosis is downstream of PDI [22, 24] . It should be noted that, even though ATP is considered to represent an indirect measurement of dense granule exposure, there is no literature evaluating the effects of PDI inhibition on granulophysin exposure. However, we did not measure ATP secretion, and this should be considered a limitation of the present study. Therefore, this set of data shows that CxxC diminishes a IIb b 3 activation without interfering with platelet granule exposure, similarly to bepristats, a novel specific anti-PDI class of compounds [17] .
We next investigated whether the effects exerted by CxxC on functional studies were attributable to an interaction with reactive thiols and/or PDI on the platelet surface. Labeling of free cysteines with MPB showed that the amount of surface thiols in resting platelets was 2.5-fold higher after incubation with TCEP, a strong membrane-impermeable thiol reductant (Fig. 5A) . Given that CxxC was in its reduced state, one could hypothesize a thiol-disulfide exchange between this peptide and oxidized thiol proteins. However, there was no alteration in MPB binding to total surface thiols when platelets were incubated with any peptide, suggesting that CxxC is not an unspecific thiol reagent (Fig. 5B) . Otherwise, considering the hypothesized association of CxxC with PDI, we revealed surface PDI in the MPB-labeled proteins. Similarly to other thiol-containing proteins, TCEP caused a four-fold increase in PDI labeling (Fig. 5C ). However, CxxC incubation decreased MPB binding to free PDI thiols by almost 30% (Fig. 5D) . Such a reduction is proportional to CxxC's effect on a IIb b 3 activation, but is lower than the observed inhibition of platelet aggregation. These results are corroborated by findings that successive thiol-disulfide exchanges between critical cysteines are crucial for platelet activation; that is, one PDI molecule may successively interact with multiple a IIb b 3 molecules [9, 25] . The lack of additive inhibition of platelet aggregation with CxxC and anti-PDI BD34 coincubation, coupled with lack of effect on total thiol MPB binding upon incubation with CxxC, supports rather specific PDI inhibition, even though other platelet isomerases should be tested in future studies. Therefore, these observations reinforce our hypothesis of a direct thiol-mediated reaction between CxxC and PDI.
We then speculated whether CxxC would covalently bind to PDI cysteines. PDI inhibition by bacitracin involves the formation of mixed disulfide bonds with Cys314 and Cys345, located in the hydrophobic pocket of the b 0 domain and linker region x, respectively [26] . Thus, LC-MS/MS studies were performed to analyze the interaction of CxxC with PDI and tentatively identify the potential binding site. When reduced human recombinant PDI [18] was incubated with CxxC, there was a mass increase of 1481 Da, corresponding to the addition of one CxxC molecule (Figs 6 and S3) . To identify the site of binding of CxxC to PDI, recombinant protein, reacted or not with CxxC, was subjected to trypsinization followed by peptide mass mapping. Mass differences were only found in the y and b series of the fragment containing Cys397 and Cys400 from the a 0 CGHC domain. According to ESI LC-MS/MS data, the PDI-derived fragment containing Cys400 showed a mass increase of 740.99 Da (1481 Da in double-charged fragments), as verified in series fragments b 16 , y 6 , y 4 , and y 2 , whereas no additional mass was found in fragment b 13 , which contained only Cys397. These data allow us to conclude that CxxC forms a mixed disulfide bond with Cys400 of PDI, even though we did not retrieve the fragment containing Cys53 and Cys56 from the a domain (Fig. S4) , which constitutes a limitation of this analysis. Nevertheless, our assumption that the effects of CxxC are attributable to its binding to Cys400, rather than Cys56, is supported by the recent demonstration that only the C-terminal active site of PDI is important for its properties in platelet function [24] .
A mixed disulfide may have two constituent thiols of different acidities. The cleavage of the mixed disulfide by a nucleophilic thiolate (RS À ) occurs favorably with release of the more acidic thiol, the less acidic group being retained in the new mixed disulfide [27] . Given that the N-terminal cysteines of PDI (Cys53 and Cys397) have a lower pK a , i.e. are more reactive, mixed disulfide bonds with these cysteines are less stable [28] . Additionally, it has been shown that Cys56 and Cys400 are involved in the stabilization of mixed disulfide bonds [29, 30] , making it reasonable to speculate that Cys397 attacks CxxC, or vice versa, to form a mixed disulfide that is, rather, stabilized at Cys400.
In conclusion, the data presented herein demonstrate that CxxC markedly inhibits platelet aggregation and activation, without interfering with granule secretion. These properties are, at least in part, ascribed to the covalent binding of CxxC to Cys400 of PDI, providingg a potential mechanism for its antiplatelet activity. Furthermore, they corroborate a recent report in which reactive cysteines of the C-terminal CGHC motif of PDI were shown to be of vital importance for thrombosis [24] . In this regard, this work may be considered to be a proof of concept that Cys400 is a potential target for site-specific drug design and the development of new antithrombotic agents. versity of Maranha˜o. The other authors state that they have no conflict of interest.
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